Is Ripretinib treatment effective?

Ripretinib has been shown to be effective in slowing disease progression in patients with advanced gastrointestinal stromal tumor (GIST) who have received at least three other drugs. Ripretinib has been shown to have a good safety profile and controllable side effects, and its benefits outweigh its risks. In a study involving 129 patients, those who received repetinib lived an average of 27.6 weeks without their disease worsening, compared with an average of 4.1 weeks for those who received a placebo. The most common side effects(are fatigue, hair loss, nausea, muscle pain, constipation, diarrhea, rash and numbness on the palms and soles of the feet, weight loss, and vomiting.